* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Medexus Pharmaceuticals's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medexus Pharmaceuticals OCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Medexus Pharmaceuticals's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Medexus Pharmaceuticals's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medexus Pharmaceuticals (MEDXF) has a OCF Margin % of 15.36% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Medexus Pharmaceuticals and its competitors. According to the industry distribution chart, Medexus Pharmaceuticals ranks #233 out of 961 companies in the Drug Manufacturers industry, placing it in the top 24.2%.
Is Medexus Pharmaceuticals' OCF Margin % too high?
Medexus Pharmaceuticals' current OCF Margin % is 15.36%. The Drug Manufacturers industry median OCF Margin % is 9.94. Medexus Pharmaceuticals' value of 15.36% is 54.5% above this industry median. Based on the distribution chart, Medexus Pharmaceuticals ranks #233 out of 961 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Medexus Pharmaceuticals has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medexus Pharmaceuticals' OCF Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Medexus Pharmaceuticals ranks #233 out of 961 companies for OCF Margin %. This places Medexus Pharmaceuticals in the top 24% of its industry — outperforming the majority of peers. The industry median OCF Margin % is 9.94. Medexus Pharmaceuticals' value of 15.36% is 54.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 9.94, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medexus Pharmaceuticals's current OCF Margin % of 15.36% is 54.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Medexus Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 9.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medexus Pharmaceuticals's current OCF Margin % is 15.36%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medexus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Medexus Pharmaceuticals (MEDXF) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.32, compared to a current price of $3.62 — trading 174.2% above its estimated fair value. The current OCF Margin % is 15.36% and 54.5% above the Drug Manufacturers industry median of 9.94. Medexus Pharmaceuticals' overall GF Score™ is 60/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Medexus Pharmaceuticals (MEDXF), the current OCF Margin % is 15.36% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medexus Pharmaceuticals (MEDXF) Overvalued in 2026?
Based on GuruFocus' analysis, Medexus Pharmaceuticals stock appears to be overvalued.
The current stock price of $3.62 is trading 174.2% above its estimated GF Value™ of $1.32.
GuruFocus considers Medexus Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for MEDXF:
OCF Margin %: 15.36%
GF Value™: $1.32 vs. price of $3.62 (174.2% above fair value)
Industry Position: 54.5% above the Drug Manufacturers median (#233 of 961)
No single metric tells the full story. See the MEDXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medexus Pharmaceuticals Inc is a specialty pharmaceutical company with a powerful North American commercial platform and a growing portfolio of inventive and rare disease treatment solutions. The company's focus is on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Medexus products are generally sold in North America to wholesalers, distributors, government agencies, healthcare facilities and specialty pharmacies.
60GF Score
Get the complete analysis for MEDXF
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEDXF has been successfully added to your 
